What should I do if I become drug-resistant after taking Selpercatinib?

Selpercatinib/Selpercatinib is a targeted drug mainly used to treat certain types of non-small cell lung cancer and thyroid cancer with RET gene alterations. Although the drug has shown good efficacy in clinical application, as the medication time is prolonged, some patients may develop drug resistance, which has an important impact on subsequent treatment options and patient prognosis.

When patients develop drug resistance after taking seputinib, detailed clinical evaluation is first required, including imaging examinations, tumor marker level monitoring, and genetic testing, aiming to confirm the mechanism of drug resistance. These mechanisms may include further changes in RET gene mutations, or activation of other signaling pathways, such as alternative activation of EGFR, ALK and other pathways. Therefore, genetic testing can provide an important basis for subsequent treatment.

After identifying mechanisms of resistance, doctors may consider adjusting treatment options. For resistance to RET gene mutations, studies have shown that other RET inhibitors can be considered, or other types of targeted drugs and chemotherapy drugs can be used in combination. For example, new targeted drugs such as crizotinib or changes to immune checkpoint inhibitors may be tried to enhance the anti-tumor effect. In addition, for some specific resistance mechanisms, drug combination therapy may also be considered in order to overcome resistance through multi-target intervention.

At the same time, supportive care is an important part of patient management. Drug resistance may lead to aggravation of symptoms. At this time, the patient's quality of life should be paid close attention to and symptomatic treatment to relieve symptoms should be given in a timely manner. At the same time, nutritional support and psychological counseling cannot be ignored to help patients better cope with the stress caused by the disease.

Reference materials:https://pubmed.ncbi.nlm.nih.gov/33082208/